CellMed AG is a
BTG International group company
Cell Therapy Delivery Programme: StemFix™
Cell therapy product development is currently hindered by inefficient delivery and poor cell retention at target tissue sites, resulting in inconsistent therapeutic benefit. We are developing StemFix™ as a point-of-care cell therapy delivery vehicle to address these challenges. StemFix™ is an innovative solution with potential application to a broad range of therapies.
